Merck shows mixed R&D signals

- Merck reported a late‑stage oncology combo failed to meet its primary endpoint in a Phase 3 study. - Investors reacted and shares fell after the Keytruda plus Lenvima kidney‑cancer study setback was reported. - At the same time, the FDA approved Merck’s once‑daily IDVYNSO HIV treatment, highlighting uneven R&D outcomes across portfolios ( ).